Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment

References

• Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., … Barbui, C. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet, 373, 746–758.
   PubMed Web of Science ®Google Scholar
• Devlin, A.M., Brain, U., Austin, J. & Oberlander, T.F. (2010). Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS ONE, 5, e12201.
   PubMed Web of Science ®Google Scholar
• Domschke, K., Tidow, N., Kuithan, H., Schwarte, K., Klauke, B., Ambree, O., … Deckert, J. (2012). Monoamine oxidase A gene DNA hypomethylation – A risk factor for panic disorder?International Journal of Neuropsychopharmacology, 15, 1217–1228.
   PubMed Web of Science ®Google Scholar
• Dreimüller, N., Tadiü, A., Dragicevic, A., Boland, K., Bondy, B., Lieb, K., … Hiemke, C. (2012). The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry, 45, 108–113.
   PubMed Web of Science ®Google Scholar
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2007). Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 9, 819–825.
   PubMed Web of Science ®Google Scholar
• Fernandes, B.S., Gama, C.S., Cereser, K.M., Yatham, L.N., Fries, G.R., Colpo, G., … Kapczinski, F. (2011). Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. Journal of Psychiatric Research, 45, 995–1004.
   PubMed Web of Science ®Google Scholar
• Fuchikami, M., Morinobu, S., Segawa, M., Okamoto, Y., Yamawaki, S., Ozaki, N., … Terao, T. (2011). DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS ONE, 6, e23881.
   PubMed Web of Science ®Google Scholar
• Garriock, H.A., Kraft, J.B., Shyn, S.I., Peters, E.J., Yokoyama, J.S., Jenkins, G.D., … Hamilton, S.P. (2010). A genomewide association study of citalopram response in major depressive disorder. Biological Psychiatry, 67, 133–138.
   PubMed Web of Science ®Google Scholar
• GENDEP Investigators, MARS Investigators & STAR*D Investigators. (2013). Common genetic variation and antidepressant efficacy in major depressive disorder: A meta-analysis of three genome-wide pharmacogenetic studies. American Journal of Psychiatry, 170, 207–217.
   Google Scholar
• Hughes, B. (2009). Novel consortium to address shortfall in innovative medicines for psychiatric disorders. Nature Reviews Drug Discovery, 8, 523–524.
   PubMedGoogle Scholar
• Ising, M., Lucae, S., Binder, E.B., Bettecken, T., Uhr, M., Ripke, S., … Müller-Myhsok, B. (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Archives of General Psychiatry, 66, 966–975.
   PubMed Web of Science ®Google Scholar
• Kang, H.J., Kim, J.M., Stewart, R., Kim, S.Y., Bae, K.Y., Kim, S.W., … Yoon, J.S. (2013). Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Progress in Neuropsychopharmacology and Biological Psychiatry, 44, 23–28.
   PubMed Web of Science ®Google Scholar
• Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.L., Licinio, J., Roots, I. & Brockmöller, J. (2004). Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 9, 442–473.
   PubMed Web of Science ®Google Scholar
• Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J.C., Pariante, C.M., … Binder, E.B. (2013). Allele-specific FKBP5 DNA demethylation mediates gene– childhood trauma interactions. Nature Neuroscience, 16, 33–41.
   PubMed Web of Science ®Google Scholar
• Laje, G. & McMahon, F.J. (2011). Genome-wide association studies of antidepressant outcome: A brief review. Progress of Neuropsychopharmacology and Biological Psychiatry, 35, 1553–1557.
   PubMed Web of Science ®Google Scholar
• Licinio, J. & Wong, M.L. (2011). Pharmacogenomics of antidepressant treatment effects. Dialogues in Clinical Neuroscience, 13, 63–71.
   PubMedGoogle Scholar
• Lopez, J.P., Mamdani, F., Labonte, B., Beaulieu, M.M., Yang, J.P., Berlim, M.T., … Turecki, G. (2013). Epigenetic regulation of BDNF expression according to antidepressant response. Molecular Psychiatry, 18, 398–399.
   PubMed Web of Science ®Google Scholar
• Melas, P.A., Rogdaki, M., Lennartsson, A., Bjork, K., Qi, H., Witasp, A., … Lavebratt, C. (2012). Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. International Journal of Neuropsychopharmacology, 15, 669–679.
   PubMed Web of Science ®Google Scholar
• Melas, P.A., Wei, Y., Wong, C.C., Sjüholm, L.K., Aberg, E., Mill, J., … Lavebratt, C. (2013). Genetic and epigenetic associations of MAOA and NR3C1 with depression and childhood adversities. International Journal of Neuropsychopharmacology, 16, 1513–1528.
   PubMed Web of Science ®Google Scholar
• Murgatroyd, C., Patchev, A.V., Wu, Y., Micale, V., Bockmuhl, Y., Fischer, D., … Spengler, D. (2009). Dynamic DNA methylation programs persistent adverse effects of early-life stress. Nature Neuroscience, 12, 1559–1566.
   PubMed Web of Science ®Google Scholar
• Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., … Memish, Z.A. (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2197–2223.
   PubMed Web of Science ®Google Scholar
• Narasimhan, S. & Lohoff, F.W. (2012). Pharmacogenetics of antidepressant drugs: Current clinical practice and future directions. Pharmacogenomics, 13, 441–464.
   PubMedGoogle Scholar
• Oberlander, T.F., Weinberg, J., Papsdorf, M., Grunau, R., Misri, S. & Devlin, A.M. (2008). Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics, 3, 97–106.
   PubMed Web of Science ®Google Scholar
• Olgiati, P., Bajo, E., Bigelli, M., De Ronchi, D. & Serretti, A. (2012). Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Progress in Neuropsychopharmacology and Biological Psychiatry, 36, 147–154.
   PubMed Web of Science ®Google Scholar
• Perlis, R.H., Patrick, A., Smoller, J.W. & Wang, P.S. (2009). When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology, 34, 2227–2236.
   PubMed Web of Science ®Google Scholar
• Perroud, N., Bondolfi, G., Uher, R., Gex-Fabry, M., Aubry, J.M., Bertschy, G., … Kosel, M. (2011). Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics, 12, 365–377.
   PubMed Web of Science ®Google Scholar
• Rodenhiser, D. & Mann, M. (2006). Epigenetics and human disease: Translating basic biology into clinical applications. Canadian Medical Association Journal, 174, 341–348.
   PubMed Web of Science ®Google Scholar
• Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., … Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163, 1905–1917.
   PubMed Web of Science ®Google Scholar
• Schroeder, M., Hillemacher, T., Bleich, S. & Frieling, H. (2012). The epigenetic code in depression: Implications for treatment. Clinical Pharmacology and Therapeutics, 91, 310–314.
   PubMed Web of Science ®Google Scholar
• Tadić, A., Müller-Engling, L., Schlicht, K.F., Kotsiari, A., Dreimüller, N., Kleimann, A., … Frieling, H. (2013). Methylation of the promoter of brain-derived neurotrophic factor exon IV and antidepressant response in major depression. Molecular Psychiatry, doi: 10.1038/mp.2013.58
   PubMedGoogle Scholar
• Tadić, A., Wagner, S., Schlicht, K.F., Peetz, D., Borysenko, L., Dreimuller, N., … Lieb, K. (2011). The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry, 35, 415–420.
   PubMed Web of Science ®Google Scholar
• Tansey, K.E., Guipponi, M., Perroud, N., Bondolfi, G., Domenici, E., Evans, D., … Uher, R. (2012). Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: A genome-wide analysis of individual-level data and a meta-analysis. PLoS Medicine, 9, e1001326.
   PubMed Web of Science ®Google Scholar
• Thomas, L., Mulligan, J., Mason, V., Tallon, D., Wiles, N., Cowen, P., … Lewis, G. (2008). Genetic and clinical predictors of treatment response in depression: The GenPod randomized trial protocol. Trial, 9, 29.
   Google Scholar
• Thomas, R.P., Recht, L. & Nagpal, S. (2013). Advances in the management of glioblastoma: The role of temozolomide and MGMT testing. Clinical Pharmacology, 5, 1–9.
   Google Scholar
• Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., … STAR*D Study Team. (2006). Evaluation of outcomes with citalopram for depression using measurement based care in STAR*D: Implications for clinical practice. American Journal of Psychiatry 2006, 163, 28–40.
   Google Scholar
• Uddin, M., Koenen, K.C., Aiello, A.E., Wildman, D.E., de los Santos, R. & Galea, S. (2011). Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychological Medicine, 41, 997–1007.
   PubMed Web of Science ®Google Scholar
• Uher, R., Perroud, N., Ng, M.Y., Hauser, J., Henigsberg, N., Maier, W., … McGuffin, P. (2010). Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. American Journal of Psychiatry, 167, 555–564.
   PubMed Web of Science ®Google Scholar
• Unternaehrer, E., Luers, P., Mill, J., Dempster, E., Meyer, A.H., Staehli, S., … Meinlschmidt, G. (2012). Dynamic changes in DNA methylation of stress-associated genes (OXTR, BDNF) after acute psychosocial stress. Translational Psychiatry, 2, e150.
   PubMed Web of Science ®Google Scholar
• van Ijzendoorn, M.H., Caspers, K., Bakermans-Kranenburg, M.J., Beach, S.R.H. & Philibert, R. (2010). Methylation matters: Interaction between methylation density and serotonin transporter genotype predicts unresolved loss or trauma. Biological Psychiatry, 68, 405–407.
   PubMed Web of Science ®Google Scholar
• Wang, D., Szyf, M., Benkelfat, C., Provencal, N., Turecki, G., Caramaschi, D., … Booij, L. (2012). Peripheral SLC6A4 DNA methylation is associated with in vivo measures of human brain serotonin synthesis and childhood physical aggression. PLoS ONE, 7, e39501.
   PubMed Web of Science ®Google Scholar
• Weaver, I.C.G., Cervoni, N., Champagne, F.A., D’Alessio, A.C., Sharma, S., Seckl, J.R., … Meaney, M.J. (2004). Epigenetic programming by maternal behavior. Nature Neuroscience, 7, 847–854.
   PubMed Web of Science ®Google Scholar
• Weizman, S., Gonda, X., Dome, P. & Faludi, G. (2012). Pharmacogenetics of antidepressive drugs: A way towards personalized treatment of major depressive disorder. Neuropsychopharmacologia Hungarica, 14, 87–101.
   PubMedGoogle Scholar
• Wiedemann, K. (2011). Biomarkers in development of psychotropic drugs. Dialogues in Clinical Neuroscience, 13, 225–234.
   PubMedGoogle Scholar